<DOC>
	<DOC>NCT00515320</DOC>
	<brief_summary>The purpose of this study is to assess the effect of fluoxetine orally dissolving tablets (ODT) on the repetitive behaviors core domain in children and adolescents with Autistic Disorder. The study will also investigate the effect of fluoxetine on the improvement of symptoms and the effects on daily living of the patient's family.</brief_summary>
	<brief_title>Study of Fluoxetine in Autism</brief_title>
	<detailed_description />
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>Meets DSMIV criteria for autistic disorder, . CYBOCSPDD score of at least 10 at screening. Diagnosis of Asperger Syndrome or Pervasive Developmental Disorder Not Otherwise Specified, Rett Syndrome, Childhood Disintegrative Disorder. Patients planning to commence cognitive behaviour therapy during the period of the study or those who have begun cognitive behaviour therapy within 8 weeks prior to enrolment. Patients who are currently taking fluoxetine or who have previously taken it are not eligible for the study. Other protocoldefined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Autism</keyword>
	<keyword>children</keyword>
	<keyword>adolescent</keyword>
	<keyword>Fluoxetine</keyword>
	<keyword>Autistic Disorder</keyword>
	<keyword>Repetitive behavior</keyword>
	<keyword>SSRI</keyword>
	<keyword>Selective Serotonin Reuptake Inhibitor</keyword>
</DOC>